Literature DB >> 15247351

Anthracycline cardiotoxicity in children.

Leontine C M Kremer1, Huib N Caron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15247351     DOI： 10.1056/NEJMp048113

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

Review 1.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

2.  Close cardiac surveillance of patients treated with anthracyclines, also necessary after chemotherapy?

Authors:  Leo H B Baur
Journal:  Int J Cardiovasc Imaging       Date:  2009-11-06       Impact factor: 2.357

3.  Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Authors:  Javier G Blanco; Can-Lan Sun; Wendy Landier; Lu Chen; Diego Esparza-Duran; Wendy Leisenring; Allison Mays; Debra L Friedman; Jill P Ginsberg; Melissa M Hudson; Joseph P Neglia; Kevin C Oeffinger; A Kim Ritchey; Doojduen Villaluna; Mary V Relling; Smita Bhatia
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

4.  Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.

Authors:  Salim Khiati; Ilaria Dalla Rosa; Carole Sourbier; Xuefei Ma; V Ashutosh Rao; Leonard M Neckers; Hongliang Zhang; Yves Pommier
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

5.  Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.

Authors:  Christopher M Schaupp; Collin C White; Gary F Merrill; Terrance J Kavanagh
Journal:  Chem Biol Interact       Date:  2014-11-21       Impact factor: 5.192

Review 6.  Chemotherapy and cardiotoxicity.

Authors:  Howard Broder; Roberta A Gottlieb; Norman E Lepor
Journal:  Rev Cardiovasc Med       Date:  2008       Impact factor: 2.930

7.  Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.

Authors:  F Aminkeng; C J D Ross; S R Rassekh; L R Brunham; J Sistonen; M-P Dube; M Ibrahim; T B Nyambo; S A Omar; A Froment; J-M Bodo; S Tishkoff; B C Carleton; M R Hayden
Journal:  Pharmacogenomics J       Date:  2013-04-16       Impact factor: 3.550

8.  Tissue and flow myocardial performance index measurements taken during dobutamine stress echocardiography for early diagnosis of late anthracycline cardiotoxicity.

Authors:  Ayşe Yildirim; F Sedef Tunaoğlu; F Güçlü Pinarli; Mustafa Ilhan; Aynur Oğuz; Ceyda Karadeniz; Rana Olguntürk; Deniz Oğuz; Serdar Kula
Journal:  Pediatr Cardiol       Date:  2009-11-24       Impact factor: 1.655

9.  Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.

Authors:  Daniel H Breysse; Ryan M Boone; Cameron M Long; Miranda E Merrill; Christopher M Schaupp; Collin C White; Terrance J Kavanagh; Edward E Schmidt; Gary F Merrill
Journal:  Drug Metab Dispos       Date:  2020-01-18       Impact factor: 3.922

10.  Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathy.

Authors:  Giuseppe Distefano
Journal:  Ital J Pediatr       Date:  2009-11-20       Impact factor: 2.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.